Today, a Director at TherapeuticsMD (TXMD), Jules Musing, sold shares of TXMD for $100.9K.
Following Jules Musing’s last TXMD Sell transaction on August 28, 2013, the stock climbed by 3.6%.
See today’s analyst top recommended stocks >>
Based on TherapeuticsMD’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $5.09 million and GAAP net loss of $39.39 million. In comparison, last year the company earned revenue of $4.12 million and had a GAAP net loss of $21.43 million. Currently, TherapeuticsMD has an average volume of 3.45M. The Company has a Price to Book ratio of 14.1036.
Jules Musing’s trades have generated a 169.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD:
